Click here to receive MS news via e-mail
Now this is different, using A cell therapy product derived from human umbilical cord blood cells may be a promising treatment approach for patients with demyelinating diseases, such as multiple sclerosis or leukodystrophy, according to a recent study developed at the Duke University Medical Center.
The study, “A cord blood monocyte–derived cell therapy product accelerates brain remyelination,” published in JCI Insight, shows that a cell product with characteristics of macrophages and microglia, the primary immune cells of the central nervous system (CNS), accelerated remyelination in mice subjected to toxic demyelination.
Microglia can exert a dual role in CNS injuries, participating in both their propagation and resolution, by modulating neuroinflammation, producing factors that regulate CNS cells, and clearing debris to provide an environment for oligondendrocytes (the myelin-producing cells) to remyelinate neurons.
Still a long way to go before any possible therapy is developed, but it’s a promising start.
MS Views and News
Providing educational information, resources and services for those affected by MS
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews